These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 15891431)

  • 1. Novel, mechanism-based therapies for cystic fibrosis.
    Rubenstein RC
    Curr Opin Pediatr; 2005 Jun; 17(3):385-92. PubMed ID: 15891431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.
    Rubenstein RC
    Mol Diagn Ther; 2006; 10(5):293-301. PubMed ID: 17022692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repairing the basic defect in cystic fibrosis - one approach is not enough.
    Farinha CM; Matos P
    FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do cystic fibrosis transmembrane conductance regulator mutations produce lung disease?
    Pilewski JM; Frizzell RA
    Curr Opin Pulm Med; 1995 Nov; 1(6):435-43. PubMed ID: 9363079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in cystic fibrosis therapies.
    Rowe SM; Clancy JP
    Curr Opin Pediatr; 2006 Dec; 18(6):604-13. PubMed ID: 17099358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapies in cystic fibrosis.
    Ratjen F; Grasemann H
    Curr Pharm Des; 2012; 18(5):614-27. PubMed ID: 22229570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of protein repair therapy in the treatment of cystic fibrosis.
    Rubenstein RC; Zeitlin PL
    Curr Opin Pediatr; 1998 Jun; 10(3):250-5. PubMed ID: 9716885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epithelium as a target for therapy in cystic fibrosis.
    Thelin WR; Boucher RC
    Curr Opin Pharmacol; 2007 Jun; 7(3):290-5. PubMed ID: 17475561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator.
    Namkung W; Kim KH; Lee MG
    Gastroenterology; 2005 Dec; 129(6):1979-90. PubMed ID: 16344066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of epithelial Na+ conductance by the cystic fibrosis transmembrane conductance regulator.
    Kunzelmann K; Schreiber R; Nitschke R; Mall M
    Pflugers Arch; 2000 Jun; 440(2):193-201. PubMed ID: 10898518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defects in processing and trafficking of cystic fibrosis transmembrane conductance regulator.
    Kunzelmann K; Nitschke R
    Exp Nephrol; 2000; 8(6):332-42. PubMed ID: 11014930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF.
    Egan ME
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1(Suppl 1):S32-S39. PubMed ID: 32681713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial cell chloride channel activity correlates with improved airway function in cystic fibrosis patients with the major mutant: Delta F508.
    Kidd JF; Bear CE
    Pediatr Res; 2002 Nov; 52(5):625-7. PubMed ID: 12409505
    [No Abstract]   [Full Text] [Related]  

  • 15. Structure-function analysis of a double-mutant cystic fibrosis transmembrane conductance regulator protein occurring in disorders related to cystic fibrosis.
    Fanen P; Clain J; Labarthe R; Hulin P; Girodon E; Pagesy P; Goossens M; Edelman A
    FEBS Lett; 1999 Jun; 452(3):371-4. PubMed ID: 10386624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy.
    Choo-Kang LR; Zeitlin PL
    Curr Opin Pulm Med; 2000 Nov; 6(6):521-9. PubMed ID: 11100963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective activation of cystic fibrosis transmembrane conductance regulator Cl- and HCO3- conductances.
    Reddy MM; Quinton PM
    JOP; 2001 Jul; 2(4 Suppl):212-8. PubMed ID: 11875262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CFTR-mediated inhibition of epithelial Na+ conductance in human colon is defective in cystic fibrosis.
    Mall M; Bleich M; Kuehr J; Brandis M; Greger R; Kunzelmann K
    Am J Physiol; 1999 Sep; 277(3):G709-16. PubMed ID: 10484398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R248G cystic fibrosis transmembrane conductance regulator mutation in three siblings presenting with recurrent acute pancreatitis and reproductive issues: a case series.
    Villalona S; Glover-López G; Ortega-García JA; Moya-Quiles R; Mondejar-López P; Martínez-Romero MC; Rigabert-Montiel M; Pastor-Vivero MD; Sánchez-Solís M
    J Med Case Rep; 2017 Feb; 11(1):42. PubMed ID: 28196530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
    Bangel-Ruland N; Tomczak K; Fernández Fernández E; Leier G; Leciejewski B; Rudolph C; Rosenecker J; Weber WM
    J Gene Med; 2013; 15(11-12):414-26. PubMed ID: 24123772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.